Publicaciones en las que colabora con Jesús Egido de los Ríos (9)

2021

  1. Interleuquina-17A: posible mediador y diana terapéutica en la hipertensión

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 41, Núm. 3, pp. 244-257

2020

  1. IL‐17A as a potential therapeutic target for patients on peritoneal dialysis

    Biomolecules, Vol. 10, Núm. 10, pp. 1-36

2018

  1. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease

    Atherosclerosis, Vol. 270, pp. 13-20

2017

  1. Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease

    Atherosclerosis, Vol. 260, pp. 130-137

2016

  1. Soluble TWEAK and major adverse cardiovascular events in patients with CKD

    Clinical Journal of the American Society of Nephrology, Vol. 11, Núm. 3, pp. 413-422

2015

  1. Paricalcitol inhibits aldosterone-induced proinflammatory factors by modulating epidermal growth factor receptor pathway in cultured tubular epithelial cells

    BioMed Research International, Vol. 2015

  2. Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases

    Atherosclerosis, Vol. 239, Núm. 2, pp. 358-363

2013

  1. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease

    Journal of Nephrology, Vol. 26, Núm. 6, pp. 1105-1113

2011

  1. Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy

    Nephrology Dialysis Transplantation, Vol. 26, Núm. 6, pp. 1797-1802